iBio, Inc. Files 8-K with Financial Updates

Ticker: IBIO · Form: 8-K · Filed: 2025-08-18T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, corporate-update

TL;DR

iBio dropped an 8-K on Aug 18th - check financials and operations.

AI Summary

On August 18, 2025, iBio, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of operations and financial condition, as well as other events and financial statements. The report was filed from their principal executive offices in San Diego, California.

Why It Matters

This 8-K filing provides investors with crucial updates on iBio, Inc.'s financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings can contain a wide range of information, from routine updates to significant corporate events, requiring careful analysis to assess risk.

Key Players & Entities

FAQ

What specific financial results or operational events are detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and 'Other Events', but specific details are not provided in the provided text.

When was the earliest event reported in this filing?

The earliest event reported was on August 18, 2025.

What is iBio, Inc.'s principal executive office address?

The principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

What were iBio, Inc.'s former company names?

The company was formerly known as iBioPharma, Inc. and InB:Biotechnologies, Inc.

What is the SIC code for iBio, Inc.?

The Standard Industrial Classification code for iBio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001104659-25-079816.txt : 20250818 0001104659-25-079816.hdr.sgml : 20250818 20250818162408 ACCESSION NUMBER: 0001104659-25-079816 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20250818 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250818 DATE AS OF CHANGE: 20250818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 251228200 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 tm2523706d1_8k.htm FORM 8-K false 0001420720 0001420720 2025-08-18 2025-08-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (date of earliest event reported): August 18, 2025   iBio, Inc. (Exact name of registrant as specified in charter)   Delaware (State or other jurisdiction of incorporation)   001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.)   11750 Sorrento Valley Road , Suite 200 San Diego , California 92121 (Address of principal executive offices and zip code)   ( 979 ) 446-0027 (Registrant’s telephone number including area code)   N/A (Former Name and Former Address)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨             Item 2.02. Results of Operations and Financial Condition.   On a preliminary unaudited basis, iBio, Inc., a Delaware company (the “Company,” “we” or “our”) expects to report that it had cash, cash equivalents and restricted cash of $8.8 million as of June 30, 2025.   The preliminary financial results above are the Company’s preliminary estimates based on currently available informatio

View on Read The Filing